Dystrophia myotonica type 1 (DM1), the most common muscular dystrophy in adults, results from expansion of a CTG repeat in the 3 0 -untranslated region of the dystrophia myotonica protein kinase gene (DMPK). Correction of the mutant DMPK transcript is a potential therapeutic strategy in DM1. We investigated the efficacy of artificial trans-splicing molecules (ATMs) to target and correct DMPK transcripts. ATMs designed to target intron 14 of DMPK pre-mRNA transcripts were tested for their ability to trans-splice the transcripts of a DMPK mini-gene construct and the endogenous DMPK transcripts of human myosarcoma cells (CCL-136). On agarose gel electrophoresis analysis, six of eight ATMs showed trans-splicing efficacy when applied to DMPK mini-gene construct transcripts, of which three were able to trans-splice endogenous DMPK pre-mRNA transcripts in myosarcoma cells, with trans-splicing efficiency ranging from 1.81 to 7.41%. These findings confirm that artificial trans-splicing can repair DMPK pre-mRNA and provide proof-of-principle evidence for this approach as potential therapeutic strategy for DM1.
Introduction
Dystrophia myotonica (DM) or myotonic dystrophy, the most common form of adult onset muscular dystrophy worldwide, is a disease with autosomal dominant inheritance characterized by progressive muscle weakness, wasting and myotonia. DM is genetically heterogeneous, with at least three genetic forms, of which DM1 is, by far, the most common. DM1 is linked to the expansion of a CTG repeat in the 3 0 -untranslated region of the dystrophia myotonica protein kinase gene (DMPK) localized on chromosome 19q13.3. 1, 2 Although it has been suggested that haploinsufficiency and position effect variegation may contribute to DM1 phenotype, there is increasing evidence that the accumulation of mutant DMPK mRNA with expanded CUG repeats [3] [4] [5] [6] [7] [8] has a central function in the pathogenetic mechanism. 9, 10 Induced expression of expanded CUG repeats in a transgenic mouse model resulted in a DM1 phenotype, which reverted to normal when the induction was switched off. 11 This provided strong evidence that blockade of mutant DMPK transcript accumulation can restore cellular functions. Thus, techniques for the correction or removal of mutant DMPK transcript are potential molecular therapeutic strategies for DM1. We examined artificial trans-splicing of corrective molecules as a molecular therapeutic strategy for DM1, namely the technique of spliceosome-mediated RNA transsplicing (SMaRT; Intronn proprietary technology, http://www.intronn.com). [12] [13] [14] [15] [16] [17] In this study, the goal is to develop a trans-splicing system for DM1 and to investigate the efficiency of artificial trans-splicing molecules (ATMs) to target and correct the DMPK transcript without degradation. Our approach provides intron-specific gene correction at the pre-mRNA level in the nucleus. ATM constructs were designed to (i) express an antisense region that specifically binds with intron 14 to prevent cis-splicing in the DMPK pre-mRNA transcript, (ii) mediate trans-splicing using artificial splicing sites and (iii) introduce coding sequences of the DMPK exon 15 and green fluorescence protein (GFP) gene. In our study, trans-splicing was achieved in DMPK transcripts generated from a DMPK mini-gene construct and from endogenous DMPK expressed in myosarcoma cells. The results suggest that this RNA-based correction approach may be a potential therapeutic strategy in DM1.
Results

Generation of ATMs
Individual plasmids expressing eight different ATMs were constructed ( Figure 1 ) and cloned into a mammalian expression vector. The ATMs were constructed with an antisense-binding region of different lengths complementary to the 3 0 end of intron 14, 3 0 -splicing elements and the coding sequence of DMPK exon 15 fused in reading frame with GFP (see Materials and Methods, and Figure 1a ). The construction of the ATMs was based primarily on the approach of Mansfield et al. 12 who had designed two types of trans-splicing molecules, carrying linear and safety spacer sequences. Likewise, we constructed four linear ATMs (ATM130, ATM166, ATM214 and ATM250), four safety ATMs (ATM130S, ATM166S, ATM214S and ATM250S) and one negative control ATM without an antisense-binding region.
Generation of the DMPK mini-gene construct
In our preliminary study, when the ATM constructs were first transiently transfected into human myosarcoma cells (CCL-136), we observed very few GFP-expressing cells and were unable to identify trans-spliced events, despite use of nested reverse transcription (RT)-PCR method. This may likely be due to low transfection efficiency of the ATM constructs. As an alternative, we constructed a DMPK mini-gene (pDMPK-T) in a mammalian expression vector to test our ATMs. This consisted of a partial sequence of DMPK exon 14, the whole intron 14, the full length of exon 15 and the 3 0 -untranslated region with 11 CTG repeats (Figure 1b) .
Trans-splicing of the DMPK mini-gene transcripts pDMPK-T and individual ATM constructs were cotransfected into CCL-136 cells. At 48 h after transfection, total RNA was isolated and analyzed for the presence of trans-spliced molecules by RT-PCR ( Figure 1c for primer positions) followed by restriction digestion of the RT-PCR product with PstI. A forward primer was designed from DMPK exon 14 (D02) and a reverse primer was designed from the GFP sequence (G03) regions such that the primers will amplify only the trans-spliced transcript, and not the normal cis-spliced DMPK transcript. The PstI sites, which were absent in the endogenous cis-splicing DMPK sequence, were introduced in ATMs at the exon 15 splice site. Successful trans-splicing would, therefore, result in a novel 420-bp fragment trans-spliced DMPK-GFP fusion mRNA transcript, which will be digested by PstI. Dystrophia myotonica type 1 pre-mRNA transcripts HY Chen et al mini-gene transcript, whereas the other two ATMs, 214 and 130S, resulted in no demonstrable product and, thus, were ineffective in trans-splicing the transcript ( Figure 2 ).
Trans-splicing of the endogenous DMPK transcripts
Although the trans-splicing events demonstrated with the DMPK mini-gene model provided proof-of-principle evidence that the ATMs were able to trans-splice a DMPK transcript, this involved a synthetic, non-endogenous model and transcript. To demonstrate ATM effectiveness and efficiency in naturally occurring endogenous DMPK pre-mRNA molecules, we created stable CCL-136 cell lines with each line expressing one of the eight ATMs. All the eight ATMs, a negative control ATM and a pEGEP-N3 plasmid backbone were linearized and transfected individually into CCL-136 cells, and stable cell lines were established using G418 selection for neomycin resistance. G418-resistant cells with specific individual constructs were pooled and expanded. From these stable cells, total RNA was isolated and analyzed for trans-spliced DMPK molecules by RT-PCR. Only cells expressing ATM250, ATM214S and ATM166 were found to produce transspliced endogenous DMPK molecules. This was confirmed by sequence analysis of the RT-PCR, to demonstrate the expected size (420-bp) product with exon 15-GFP sequence of the ATM linked to exon 14 ( Figures 3 and 4) .
Efficiency of trans-splicing of endogenous DMPK transcripts
Real-time RT-PCR analysis was performed to estimate the proportion of transcripts that were trans-spliced. A common forward primer and two sequence-specific reverse primers were used for the quantification of total and trans-spliced DMPK transcripts by real-time RT-PCR amplification. To assay total DMPK transcript, a common forward primer (D02) located in exon 14 and a reverse primer common for both cis-and trans-spliced products located in exon 15 (D03) were used. To assay for transspliced DMPK product, a reverse primer located in the GFP sequence (G03) was used. Successful amplification was verified by agarose gel electrophoresis, which resulted in a specific band of the expected size Trans-splicing of endogenous DMPK pre-mRNA. CCL-136 cells were separately transfected with 2 mg each of eight linearized plasmids expressing artificial trans-splicing molecules (ATMs) and two control plasmids. Stable cell lines were established using G418 selection for neomycin resistance. G418-resistant cells with specific individual constructs were pooled and expanded. From these stable cells, total RNA was isolated and analyzed for the presence of trans-spliced molecules by reverse transcription (RT)-PCR. Only cells expressing ATM250, ATM214S and ATM166 were found to produce demonstrable trans-spliced endogenous DMPK molecules by agarose gel electrophoresis. The arrow indicates the trans-spliced products.
Dystrophia myotonica type 1 pre-mRNA transcripts HY Chen et al (cis-spliced 185 bp, trans-spliced 420 bp). Genomic DNA co-amplification did not occur during RT-PCR.
To quantify the number of molecules of total and transspliced DMPK transcripts, we established two different standard curves. A cDNA fragment containing DMPK exons 14, 15 and GFP sequences was used as a template reference sample for the standard curves. Real-time PCR amplification using the SYBR Green I Master mix resulted in standard curves showing minimum sensitivity to 37 molecules and maximum to 3.7 Â 10 5 molecules, the maximum amount that could be quantified to keep the standard curve linear. In all cases, the PCR efficiency was between 90 and 100% (À3.64slope4À3.1). Accuracy of the standard curves was evaluated by analyzing standard dilution points with known reference samples and unknown test samples.
Quantities of the trans-spliced transcripts were expressed as a relative number of molecules normalized to the number of total DMPK transcripts. In CCL-136 cells, the DMPK copy number ranged from 30 to 1320 molecules per ng of total RNA and trans-spliced molecules ranged from 0.05 to 219 molecules per ng of total RNA. The trans-splicing efficiency varied from 0.02 to 7.41% (ATM214S-1.81%, ATM214-0.02%, ATM250S-0.02%, ATM250-6.56%, ATM130S-0.07%, ATM130-0.46%, ATM166S-0.03% and ATM166-7.41%). The ATMs carrying safety molecule showed up to 1.81% of trans-splicing, whereas the ATMs with linear molecule showed higher trans-splicing efficiency of up to 7.41% ( Figure 5 ).
Discussion
Artificial trans-splicing technology is a novel approach for the correction of genetic diseases at the pre-mRNA level by direct repair or reprogramming of endogenous genetic defects at transcription levels without silencing gene expression by degradation. 18 SMaRT has been shown to repair defective pre-mRNA molecules in cultured mammalian cells, xenografts and animal models of human disease including cystic fibrosis, 12 hemophilia A (factor VIII deficiency), 13 X-linked CD40 ligand immunodeficiency, 14 human apolipoprotein A1, 15 DNA protein kinase deficiency, 19 epidermolysis bullosa simplex with muscular dystrophy 20 and spinal muscular atrophy. 21 In DM1, a strategy to remove or correct mutant mRNA is appropriate in view of evidence that the accumulation of mutant mRNA in the nucleus is the primary basis of the disease. 3, 22 Approaches targeted at the mRNA level to remove mutant mRNA, namely the use of antisense, 23 nuclear-retained hammerhead ribozyme 4 and siRNA, 5 have been shown to be able to remove mutant mRNA in in vitro DM1 cells. However, the removal of wild-type mRNA together with mutant mRNA that occurs with all these techniques may have potential untoward consequences. Evidence for this was raised by the presence of mild myopathy and cardiac Exon 14 Exon 15
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GFP from pEGFP-N3 Figure 4 The sequence of the trans-spliced endogenous DMPK product. Trans-spliced molecules were generated by reverse transcription (RT)-PCR from stable cell lines expressing ATM250, ATM214S and ATM166. DMPK exon 14, exon 15 and multiple cloning sites and the GFP sequence are shown. ATMs Rate (%) Figure 5 Efficiency of DMPK pre-mRNA trans-splicing. Total RNA was extracted from stable cell lines expressing artificial transsplicing molecules (ATMs) and control plasmids. Total RNA (3 mg) from each cell line were reversed transcribed using oligo(dT) 12À18 and the efficiency of DMPK RNA trans-splicing was analyzed by absolute quantitative real-time RT-PCR. The trans-splicing efficiency varied from 0.02 to 7.41% (ATM214S-1.81%; ATM214-0.02%; ATM250S-0.02%; ATM250-6.56%; ATM130S-0.07%; ATM130-0.46%; ATM166S-0.03%; ATM166-7.41%).
Dystrophia myotonica type 1 pre-mRNA transcripts HY Chen et al conduction abnormality in DMPK knockout mice with absence of DMPK expression, although these mice did not show other DM1 features such as myotonia or cataracts. 24, 25 Hence, the trans-splicing approach, which will correct mutant DMPK pre-mRNA without removal of wild-type pre-mRNA may be an attractive alternative approach.
To date, there have been no reports of trans-splicing being applied effectively to correct DMPK pre-mRNA. Our study demonstrated that some of the ATMs designed in our study were able to trans-splice DMPK pre-mRNA derived from a DMPK mini-gene or derived endogenously from myosarcoma cells. The endogenous DMPK pre-mRNA trans-splicing efficiency of the efficacious ATMs ranged from 0.46% to a maximum of 7.41%. Although this level of mRNA correction is low, the minimum level of correction needed to result in a phenotype change in DM1 is not known. On the other hand, these results offer proof-of-principle evidence that pre-mRNA trans-splicing of DMPK pre-mRNA is feasible and, therefore, potentially applicable as a therapeutic strategy in myotonic dystrophy.
The efficiency of RNA trans-splicing may be significantly influenced by many factors, including concentrations of the target and ATM, the accessibility of the binding domain, the strength of the ATM splice elements, the strength of the target splice sites and the route of ATM delivery. In our study, more ATMs were effective in trans-splicing pre-mRNA of truncated DMPK mini-gene than in the case of endogenous DMPK premRNA of myosarcoma cells. This is not unexpected as the transiently transfected truncated DMPK mini-gene offered more targets for trans-splicing. Previously reported experiments using co-transfecting mini-gene targets and ATMs have also demonstrated high levels of RNA trans-splicing compared to endogenous premRNA trans-splicing, with efficiency ranging from 1 to 80% based on real-time RT-PCR detection. 12, 26, 27 However, the efficiency of trans-splicing to an endogenous pre-mRNA target expressed in a stable cell line has generally been lower; with reports of between 3 and 7% efficiency when assayed by PCR, 13, 26 which is comparable to the maximum trans-splicing efficiency achieved in our study.
All ATMs designed in our study included a yeast branch point (BP) consensus sequence, a polypyrimidine tract (PPT) and 3 0 splice site (3 0 SS). 12 Four different lengths of antisense-binding domain regions were designed to target intron 14 and at least one of two predicted U2-binding domains. We predicted two U2-binding domains in DMPK intron 14, namely (CTAAC) located at À138 to À134 bp (PU2) and a reverse sequence complimentary to AGCCAATCGA located at À49 to À39 bp (PU2r) from exon 15. Two ATMs, ATM166 (from À180 to À14) and ATM250 (from À264 to À14), designed to block both PU2 and PU2r domains showed 7.41 and 6.56% of trans-splicing efficiency respectively. On the other hand, two other ATMs, ATM214S (from À264 to À50) and ATM130S (from À180 to À50), designed to block only PU2, showed only 1.81 and 0.46% of transsplicing events, respectively. ATM214 (from À264 to À50) and ATM130 (from À180 to À50) showed no transsplicing with both transiently and endogenously expressed DMPK target transcript. These observations suggest that, of the two predicted U2-binding sites, the PU2r sequence region is the more relevant in cis-splicing.
In a previously reported study, an internal inverted repeats site (safety molecule) was introduced in the transsplicing domain to enhance trans-splicing specificity as well as efficiency. 28 In our study, we included this safety molecule in four of the eight ATMs. We observed only a single specific trans-spliced RT-PCR product with ATMs with the safety molecule. Hence, this safety molecule does not appear to be necessary to ensure trans-splicing specificity. However, the efficiency of trans-splicing by ATMs with the safety molecule was generally lower than the ATMs without the safety molecule. This is consistent with observations in a previously reported study, which concluded that the presence of the safety molecule was associated with reduced trans-splicing efficiency. 28 In conclusion, we have shown that our ATMs can specifically target and trans-splice DMPK pre-mRNA. Although the amount of trans-splicing achieved was not high, the findings offered support for the potential of trans-splicing as a novel therapeutic strategy in myotonic dystrophy. Further support for the use of this strategy will require the demonstration of correction of mutant DMPK transcripts and reversal of DM1 phenotype and cellular function in vitro in patients' cells and, subsequently, in in vivo animal models and patients.
Materials and methods
Target construction and ATMs
To generate mammalian expression, DMPK mini-gene target construct (pDMPK-T) (Figure 2 ), a 1-kb genomic fragment, was amplified using DMPK exon 14 For (5 0 -GCCAGGCCCCATGCACCGCCGC-3 0 ), DMPK U3R (5 0 -CTTTGCACTTTGCGAACCAACG-3 0 ) primers, subcloned into pGEM-T-Easy Vector (Promega, Madison, WI, USA) and sequenced. This fragment was then excised by using NotI restriction enzyme (New England Biolabs, Hitchin, Herts, UK), subcloned into mammalian expression plasmid pREP10 and cloned orientation was confirmed using PstI digestion and DNA sequencing.
ATM (Figure 1 ) expression constructs were created from an antisense-binding domain linked to the coding sequence of DMPK exon 15 by artificial trans-splicing elements. The trans-splicing elements included a yeast BP consensus sequence, a PPT and 3 0 SS as proposed by Mansfield et al. 12 The BP, PPT and 3 0 SS sequences were created from four different oligodeoxynucleotide primers that were annealed and ligated into KpnI and BamHI sites of mammalian expression plasmid pEGFP-N3 (Clontech, Palo Alto, CA, USA) to generate a construct termed pSE-G. The antisense-binding domain, complementary to an intron 14 sequence encompassing the U2-binding domains were generated by PCR from normal human genomic DNA using primers flanked with HindIII and KpnI sites and subcloned into pSE-G at the 5 0 end of the splice element to generate a construct termed pBD-SE-G. The coding sequence of exon 15 was amplified from human genomic DNA using primers flanked with PstI sites and subcloned into pBD-SE-G in reading frame with GFP sequence to generate an ATM expression construct. Four different ATM constructs were developed with each defined by a specific antisense-binding domain, namely, ATM130 with the Dystrophia myotonica type 1 pre-mRNA transcripts HY Chen et al domain binding to nucleotides À180 to -50, ATM166 binding to nucleotides À180 to À14, ATM214 binding to nucleotides À264 to À50 and ATM250 binding to nucleotides À264 to À14 (ATM250), of human DMPK intron 14. The nucleotide numbers of intron 14 referred to upstream sequence from DMPK exon 15 start point. In all four ATMs, a 31-bp inverted repeats sequence (safety molecule) was inserted in between the antisense-binding domain and trans-splicing elements. ATMs carrying the safety molecule are referred to as 'safety' ATMs and those without the safety molecule are referred to as 'linear' ATMs.
Cell culture and transfections
Human myosarcoma cells (CCL-136 from ATCC, Manassas, VA, USA) were grown at 37 1C and 5% CO 2 in a humidified incubator in Dulbecco's modified Eagle's medium with 4 mM L-glutamine, 4.5 g l À1 glucose, 1.5 g l À1 sodium bicarbonate and 10% fetal calf serum. Passaging of the cells was performed every 3-4 days using 1% trypsin-EDTA. Prior to transfection, cells were plated at desired density (1.5 Â 10 6 cells per 60 mm poly-D-lysine-coated per well) and grown for 24 h. Cells were transfected with 0.5 mg pDMPK-T and 1.5 mg ATM plasmids using LipofectaminePlus reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. At 48 h after transfection, the wells were rinsed once with phosphate-buffered saline and the cells were harvested with 1 ml phosphate-buffered saline. Total RNA was isolated from pelleted cells using Trizol reagent (Invitrogen).
To establish stable cell lines expressing ATMs, CCL-136 cells were transfected with 2 mg of linearized ATM plasmids using LipofectaminePlus as described above. At 48 h after the transfection, cells were cultured in fresh medium containing 300 mg ml À1 G418 (Invitrogen). This selection procedure was then repeated over a period of 4 weeks.
RT-PCR
Total RNA (3 mg) obtained from the transient transfection experiments was reverse transcribed using oligo(dT) and Superscript First-Strand synthesis system (Invitrogen) according to the manufacturer's protocol. Nested PCR was employed for amplification of cDNA. The first round PCR used DMPK exon 12 (D01For: 5 0 -TGGAG GAGGAGGTGCTCACC-3 0 ) and GFP (G01Rev: 5 0 -AGAA GATGGTGCGCTCCTGG-3 0 ) specific primers and the second round PCR used exon 14 (D02For: 5 0 -GCCA GGCCCCATGCACCGCCGC-3 0 ) and GFP (G02Rev: 5 0 -TAGCGGCTGAAGCACTGCAC-3 0 ) primers.
Quantitative real-time RT-PCR mRNA levels were measured by absolute quantitative real-time RT-PCR method using Power Syber Green PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA). A positive control DMPK cDNA fragment including exons 14, 15 and GFP sequence was cloned into the pGEM-T easy vector (Promega) to generate pEG-T easy.
The molar concentration and copy number of the plasmid pEG-T easy were calculated on the basis of the molecular weight of the plasmid measured at A 260 nm . As a reference sample, the pEG-T easy was 10-fold serially diluted (from 10 À5 to 10 À9 ) and used to generate standard curves. Real-time PCR was performed and analyzed on an ABI prism7900HT Sequence Detector system according to the manufacturer's protocol (Applied Biosystems). In each experiment, duplicates of a standard dilution series of pEG-T easy and first strand cDNA generated from 600 ng of total RNA of test samples were amplified in a 20 ml reaction containing 100 nM of each primers. Primers for exon 14 (D02For) and exon 15 (D03 Rev: 5 0 -CAGACTGCGGTGAGTTGGCC-3 0 ) were used to measure the total DMPK transcription molecules (both cisand trans-spliced molecules). Primers for exon 14 (D02For) and GFP (G03 Rev: 5 0 -CGTCCAGCTCGAC CAGGAT-3 0 ) were used to calculate the novel recombinant DMPK-GFP fusion molecules (that is, the transspliced molecules).
Sequencing of the PCR products
Constructs and RT-PCR products were sequenced to confirm the product specificity using M13 forward-, reverse-and exon-specific primers. Sequence reactions were carried out using the BigDye terminator cycle sequencing kit (Applied Biosystems) according to the manufacturer's protocol. The sequencing products were separated on the automatic sequencer ABI3100 (Applied Biosystems) under standard run conditions.
